Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin added to endocrine-based first-line therapy for advanced ER-positive/HER2-negative breast cancer
2016-000494-20Phase 2Completed
- Sponsor
- Skåne University Hospital
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in breast cancer (2 arms), sponsored by Skåne University Hospital. Primary endpoint: Clinical benefit rate. Started May 2016; status: completed.
02
Drugs
atorvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-000494-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000494-20.